Skip to main content
PVgenix
Why PVgenix

Modern technology, lower cost, no compliance compromise

PVgenix delivers a complete, GxP-aligned drug-safety platform at a significantly lower total cost than older systems — without compromising on compliance.

Lower TCOCloud-nativeGxP-aligned
PVgenix · total cost of ownershipup to 60% lower
Relative 3-year cost (indicative)
100
Legacy enterprisehigh licence + infra
~65
Mid-marketmoderate cost
~40
PVgenixlow platform + hosting
~0
Month to delivery
0
Client servers (SaaS)
0%
Audit coverage
Three advantages, one platform

Equivalent capability, modern stack, lower cost

The cost, technology, and compliance case for moving core drug-safety operations to PVgenix.

01Cost advantage

Enterprise-grade safety, without enterprise pricing

Low platform and licensing cost suited to CROs, small-to-mid pharma, and complete-license buyers — with efficient modern infrastructure that keeps hosting and total cost of ownership down.

  • Low platform / licensing cost
  • Low server / hosting cost
  • No heavy per-seat enterprise licensing
  • Lower total cost of ownership
Legacy
100
Mid-market
~65
PVgenix
~40
Indicative relative total cost of ownership
02Modern technology

Cloud-native, multi-tenant, AI-assisted

Built on current-generation frameworks with an efficient, optimized hosting model — and AI-assisted intake and extraction under human-in-the-loop control, where many older systems remain fully manual.

  • Current-generation application architecture
  • Cloud-native multi-tenant design
  • Efficient, optimized hosting model
  • AI-assisted workflows with human control
PVgenix cloudmulti-tenant · auto-scalingTenant AisolatedTenant BisolatedTenant Cisolated
One codebase, isolated tenants, elastic scale
03GxP without compromise

Modern stack, full compliance posture

Modern technology does not come at the expense of compliance. PVgenix is designed around GxP, GAMP 5, and 21 CFR Part 11 principles, with complete audit logging, RBAC, and a supporting validation documentation package.

  • GxP, GAMP 5 & 21 CFR Part 11 principles
  • Complete audit logging and RBAC
  • Supporting validation documentation package
21 CFR Part 11
GAMP 5 lifecycle
EU GVP modules
Audit-ready by design
Validation-ready, with the documentation to prove it
By category, not by vendor

How PVgenix compares across the lifecycle

A category-level comparison against legacy enterprise platforms and other mid-market systems — equivalent core capability, on a modern stack, at a lower cost profile.

PVgenixModern · cost-effective
Legacy enterpriseHigh cost
Other mid-marketMixed
Setup time
Minutes (new tenant)
Several months
Weeks
AI-assisted intake
Built-in
Being added
Limited
Built-in AS2 gateway
Yes
Often add-on
Varies
Straight-through processing
Qualifying cases
Premium
Limited
Literature monitoring
AI-assisted
Premium add-on
Varies
Dedicated + SaaS
Both models
Mostly one
Mostly SaaS
Validation documentation
Provided
High cost
Varies
Technology stack
Modern / current
Older generation
Mixed
Hosting / server cost
Low
High
Moderate
Target cost profile
Cost-effective
High
Moderate

PVgenix is validation-ready and audit-ready: it ships with a complete IQ/OQ/PQ documentation package to support client-led validation. "Validated" is a state achieved only after qualification is executed in a specific client environment.

The core advantage

Many existing safety systems run on older technology and older server and cost models. PVgenix delivers equivalent core drug-safety capability on modern technology, at a lower platform and hosting cost, while remaining GxP-aligned — the best cost-saving option for CROs, pharma companies, and clients purchasing a complete license.

~0%
Lower total cost vs. legacy
~0
Month to delivery
0%
Audit coverage
0
Deployment models

Build the business case for PVgenix

Request a demo to walk through the cost and technology advantage against your current platform.